Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform
Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life science research, announced that it has received a $200K grant from the National Cancer Institute (NCI) for the development of a rare cell isolation platform for diagnostic and research applications. The Phase One Small Business Innovation Research Grant will enable Fluxion to further develop its innovative microfluidic platform. The endpoints of this research include enhanced methods for detecting circulating tumor cells that appear in very low concentrations in the early stages of cancer.
generic viagra online
New Alliance For Discovery Of WNT Pathway Inhibitors To Be Used In Cancer Therapy
Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets. Drugshop to buy zoloft online and other pills.
News of the day
REMERON(R) Now Approved In Japan For The Treatment Of Depression In Adult Patients
Schering-Plough Corporation (NYSE: SGP) announced that Schering-Plough K.K., the company"s country operation in Japan, has received marketing approval for REMERON(R) /Reflex(R) (mirtazapine)15 mg Tablets for the treatment of major depressive disorder.(1) The product was developed jointly with Meiji Seika Kabushiki Kaisha, Ltd. Schering-Plough and Meiji Seika will market the product under the trade names, REMERON(R) and Reflex(R), respectively. REMERON is currently available in more than 90 countries worldwide.
Nutrition

Infection Prevention Text Updated, Improved - The APIC Text Of Infection Control And Epidemiology

More than 300 infection prevention experts have completed a text that serves as one of the most valuable tools for infection preventionists throughout the world, the APIC Text of Infection Control and Epidemiology. The 1,700-page document, now in its 3rd edition, has been completely revised and is now available, offering a concise information re containing more than 120 expanded and enhanced chapters. Published by the Association for Professionals in Infection Control and Epidemiology (APIC), the APIC Text contains new chapters addressing infection prevention in ophthalmology, the physician"s office and interventional radiology. Each chapter is peer-reviewed and contains an abstract, references, international perspectives and additional res. "This was an immense undertaking," said APIC 2009 President Christine J. Nutty, RN, MSN, CIC. "The APIC Text compiles the evidence-based literature in one convenient location and can be used to educate all healthcare personnel on the essentials of infection prevention. It is the definitive, comprehensive, go-to covering every aspect of infection prevention and control." The 3rd edition of the APIC Text has been updated to include the most current regulations, guidelines, technology, research and best practices in the field of infection prevention. It also includes specific information for ambulatory care and long-term care facilities, res for staffing and training and analysis of new technologies. Each chapter focuses on the needs of infection preventionists new to the field and then builds on the basic concepts, providing advanced information for more experienced preventionists. APIC will release an online version of the APIC Text in the fall of 2009. This electronic version will be updated regularly and accessible anywhere. Purchase of the APIC Text includes a one-year subscription to the APIC Text Online. Visit http://www.apic.org/text for more information. APIC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009